-
Radioconjugates: Targeting for Precision
Suzanne Elvidge
May 06, 2025
The development of radioconjugates – targeted molecules designed to carry radionuclides directly to cancerous cells, lowering systemic exposure and increasing the precision of treatment.
-
Now and Next in Type 2 Diabetes
Suzanne Elvidge
May 06, 2025
Type 2 diabetes, the most common form of diabetes, affects more than 800 million adults worldwide.
-
Oncolytic viruses in cancer treatment
Suzanne Elvidge
April 21, 2025
Naturally occurring oncolytic viruses, which replicate in tumour cells and trigger apoptosis and immune responses while sparing healthy cells, were first discovered at the turn of the 19th century.
-
Molecular Editing in Drug Discovery: Making Peripheral and Skeletal Changes
Suzanne Elvidge
April 01, 2025
Drug discovery often begins with high-throughput screening of large libraries to identify potential hits.
-
Falling off the Patent Cliff: Patent Expirations in 2025 and Onwards
Suzanne Elvidge
March 31, 2025
In the early 2010s, a new phenomenon hit the pharmaceutical industry – the patent cliff.
-
Moving Forward in Translational Models
Suzanne Elvidge
March 03, 2025
Translational medicine aims to bridge the gap between basic and clinical science. New translational models help predict drug efficacy and safety, but need collaboration.
-
Working in Rare Diseases: A Business Model
Suzanne Elvidge
February 28, 2025
Rare diseases, by definition, affect a small population.
-
The Role of Biosimilars
Suzanne Elvidge
February 12, 2025
Biological drugs are therapeutics that are made by living organisms or are created from cells and tissues, and include therapeutic proteins and monoclonal antibodies.
-
The Value of Streamlining Manufacturing
Suzanne Elvidge
February 12, 2025
Drug manufacturing makes up a significant part of what it costs to develop drugs. As expenditures for ingredients, power, equipment, rent and staff increase, companies are working hard to find ways to cut outlays through streamlining.
-
Making Sense of Antisense: The Power of Gene Silencing
Suzanne Elvidge
February 11, 2025
This article explores antisense oligonucleotides (ASOs) in gene silencing, covering their mechanism, development, applications, pros and cons, and future delivery challenges.